Integrated Safety Analysis of Abrocitinib in 3850 Patients With Moderate-To-Severe Atopic Dermatitis: Data From More Than 9600 Patient-Years With Up to 6.5 Years of Exposure. J of Skin [Internet]. 2025 Nov. 10 [cited 2026 Apr. 19];9(6):s616. Available from: https://skin.dermsquared.com/skin/article/view/3820